IL-23/IL-27 ratio in peripheral blood of patients with breast cancer

Iranian Journal of Medical Sciences

Volumn 39, Issue 4, 2014, Pages 350-356

  Khodadadi, Ali ^a   Razmkhah, Mahboobeh ^b   Eskandari, Ali Reza ^a   Hosseini, Ahmad ^b   Habibagahi, Mojtaba ^c   Ghaderi, Abbas ^c   Jaberipour, Mansooreh ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast neoplasm; Interleukin 23; Interleukin 27; Neoplasms

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 23; INTERLEUKIN 27;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MIDDLE AGED; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 84904009393     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Trinchieri G, Pfanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19:641-644. PubMed PMID: 14614851.
2. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clinical Clin Dev Immunol. 2010;2010:832454. doi: 10.1155/2010/832454. PubMed PMID: 20885915; PubMed Central PMCID: PMC2946577.
3. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230. doi: 10.1084/jem.178.4.1223. PubMed PMID: 8104230; PubMed Central PMCID: PMC2191194.
4. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155-168. doi: 10.1016/S1359-6101(01)00032-6. PubMed PMID: 11900991.
5. Pfanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16:779-790. doi: 10.1016/S1074-7613(02)00324-2. PubMed PMID: 12121660.
6. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol. 2005;175:2191-2200. doi: 10.4049/ jimmunol.175.4.2191. PubMed PMID: 16081786.
7. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 2003;170:4886-4890. doi: 10.4049/jimmunol.170.10.4886. PubMed PMID: 12734330.
8. Artis D, Villarino A, Silverman M, He W, Thornton EM, Mu S, et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol. 2004;173:5626-5634. doi: 10.4049/jimmunol.173.9.5626. PubMed PMID: 15494513.
9. Yoshimoto T, Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic infammation. J Immunol. 2007;179:4415-4423. doi: 10.4049/jimmunol.179.7.4415. PubMed PMID: 17878337.
10. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7:929-936. doi: 10.1038/ni1375. PubMed PMID: 16906167.
11. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic infammation of the central nervous system. Nat Immunol. 2006;7:937-945. doi: 10.1038/ni1376. PubMed PMID: 16906166.
12. Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, Takeda A, et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinfammatory cytokine production. Immunity. 2003;19:657-667. doi: 10.1016/S1074-7613(03)00298-X. PubMed PMID: 14614853.
13. Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sauvage FJ, Hunter CA. IL-27 limits IL-2 production during Th1 differentiation. J Immunol. 2006;176:237-247. doi: 10.4049/jimmunol.176.1.237. PubMed PMID: 163 6 5 415.
14. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725. doi: 10.1016/S1074-7613(00)00070-4. PubMed P M I D: 11114 3 8 3.
15. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. Journal J Biol Chem. 2003;278:1910-1914. doi: 10.1074/ jbc.M207577200. PubMed PMID: 12417590.
16. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal infammation and acanthosis. Nature. 2007;445:648-651. PubMed PMID: 17187052.
17. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359-2370. doi: 10.1053/j.gastro.2007.03.104. PubMed PMID: 17570211.
18. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238. doi: 10.1038/nature04753. PubMed PMID: 16648838.
19. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231-234. PubMed PMID: 16648837.
20. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of infammation. Annu Rev Immunol. 2007;25:221-242. doi: 10.1146/annurev.immunol.22.012703.104758. PubMed PMID: 17291186.
21. Greene FL, Balch CM, Fleming ID, April F. Eztnm for the Ajcc Cancer Staging Manual. 6th ed. Berlin: Springer-Verlag GmbH; 2003.
22. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specifc primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134. doi: 10.1186/1471-2105-13-134. PubMed PMID: 22708584; PubMed Central PMCID: PMC3412702.
23. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res. 2010;16:4188-4197. doi: 10.1158/1078-0432.CCR-10-0173. PubMed PMID: 20587591.
24. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol. 2006;176:7317-7324. doi: 10.4049/jimmunol.176.12.7317. PubMed PMID: 16751375.
25. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006;66:6395-6404. doi: 10.1158/0008-5472. CAN-05-4087. PubMed PMID: 16778218.
26. Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specifc CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol. 2009;182:4328-4338. doi: 10.4049/ jimmunol.0800471. PubMed PMID: 19299733; PubMed Central PMCID: PMC2730673.
27. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, et al. Antiproliferative activity of IL-27 on melanoma. J Immunol. 2008;180:6527-6535. doi: 10.4049/ jimmunol.180.10.6527. PubMed PMID: 18453571.
28. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461-465. doi: 10.1038/nature04808. PubMed PMID: 16688182.
29. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003;171:600-607. PubMed PMID: 12847224.
30. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol. 2007;178:7571-7580. doi: 10.4049/ jimmunol.178.12.7571. PubMed PMID: 175 48592.
31. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 2007;28:207-212. doi: 10.1016/j.it.2007.03.006. PubMed PMID: 17395538.
32. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008;374:533-537. doi: 10.1016/j. bbrc.2008.07.060. PubMed PMID: 18655770.
33. Ljujic B, Radosavljevic G, Jovanovic I, Pavlovic S, Zdravkovic N, Milovanovic M, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010;41:182-189. doi: 10.1016/j.arcmed.2010.02.009. PubMed PMID: 20 682175.
34. Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinfammatory pathway. J Immunol. 2008;180:7175-7183. doi: 10.4049/jimmunol.180.11.7175. PubMed PMID: 18490716.
35. Fukuda M, Ehara M, Suzuki S, Ohmori Y, Sakashita H. IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity. Int J Oncol. 2010;36:1355-1365. doi: 10.3892/ijo_00000620. PubMed PMID: 20428758.